By looking at the oncology drug approvals by the FDA in the last 22 years, there has been a clear increase in the adoption of biomarker-defined patients populations. #PrecisionMedicine #PrecisionOncology nature.com/articles/s4157…

📢 [Press release] @Transgene appoints two Seasoned Leaders in #Oncology Emmanuelle Dochy as Chief Medical Officer (CMO) and Maurizio Ceppi, PhD as Chief Scientific Officer (CSO).

Back from ASCO, Maurizio Ceppi, PhD, PhD, CSO of Transgene shares insights from his experience.

📢 Transgene – LCI « Des résultats extrêmement encourageants », un vaccin pour lutter contre la récidive du cancer porte de l'espoir. Ce vaccin thérapeutique individualisé contre le cancer pour lutter contre les cancers ORL est un vaccin conçu et développé par Transgene.

ASCO 2025: @Brad Loncar interviewed @Alessandro Riva, Chairman and CEO of @Transgene. @transgene is proud to share this really great interview broadcasted on BiotechTV. Full interview 🎤 shorturl.at/iudPf

📢Transgene is proud to be part of the new edition of Nature Biotechnology, published June 10, 2025. This article offers excellent visibility for our individualized therapeutic vaccine, TG4050 designed and developed by Transgene. 📰 Read👉 shorturl.at/pWxmf

📢 Transgene and BioInvent International to Present a Poster about updated clinical results of BT-001 at ESMO - Eur. Oncology , to be held in Berlin from 17 to 21 October 2025. Poster #2828 📰 Press Release 👉 shorturl.at/81fa0 ESMO Online programme 👉 shorturl.at/JXL5b

🎥 📷 Belle journée pour Transgene qui a ouvert ses portes ce mercredi à des journalistes parisiens et locaux ainsi qu’à des photographes et cameramen de tous horizons. 👉 Pour en savoir plus, procurez-vous les derniers numéros ! 🗞️

🎤 Excited to announce that Maurizio Ceppi, PhD, PhD, CSO at Transgene will be speaking at the Festival of Biologics, Europe’s largest biological event taking place in Basel. He will talk about our individualized neoantigen therapeutic vaccine #TG4050. 👉shorturl.at/zMc95

Maurizio Ceppi è direttore scientifico dell’azienda biotech Transgene per cui guida lo sviluppo di vaccini personalizzati contro il cancro grazie all’intelligenza artificiale. A @TEDxBellinzona sostituirà, tra i relatori, Immanuel Casto cdt.ch/news/ticino/la…

I’m truly grateful for the privilege of speaking at @TEDxBellinzona. My talk - "What will I be when I grow up? The magic of DNA. The challenge of cancer.” - was about my journey from a childhood fascination with DNA to my current research on personalized cancer vaccines.

cdt.ch/news/ticino/ca…

In September 1928 Alexander Fleming returned from holiday to a curious sight. He saw that bacteria he had been growing on a culture plate had been killed in an area close to where a mould was accidentally growing. It was to be a monumental discovery – Alexander Fleming had just

10 days have passed after my participation at TEDx Bellinzona and I can still feel the excitement and the vibe related to that event! Thanks again to the organizers for the opportunity to tell my journey as a scientist to a big audience…

🎤 I’ll be speaking at Festival of Biologics Basel 2025, tomorrow, the 2nd of September at 9.05am (Immunotherapy Keynotes, Theatre 9). I will give a talk on the progress of Transgene’s clinical asset TG4050, currently tested in a Phase 2 adjuvant study in HNSCC patients.

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

👍 Transgene recently published in Frontiers! “TG6002 oncolytic vaccinia virus and chemotherapy synergy: a promising strategy for pancreatic ductal adenocarcinoma” 👉Read the article : shorturl.at/FxP8N

Cosa farai da grande? La magia del DNA, la sfida del cancro | Maurizio C... youtu.be/bU0wJdNzIlg?si… via YouTube My TEDx talk is about my journey from childhood fascination with DNA, through gene therapy and mRNA vaccines, to my current research on personalized cancer vaccines.

📢 Transgene and BioInvent International to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001 at ESMO - Eur. Oncology, to be held in Berlin from 17 to 21 October 2025. 📰 Press Release 👉 shorturl.at/dgA6H